Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety (Location-F)
Diabetes Type 2
About this trial
This is an interventional treatment trial for Diabetes Type 2 focused on measuring diabetes type 2
Eligibility Criteria
Inclusion Criteria: type 2 diabetic patients between the ages of 20 and 80 who are taking oral diabetes medications (metformin and/or DPP-4 inhibitors) for more than 8 weeks without dose adjustment body mass index (BMI) ≥ 20 kg/m2 eGFR ≥ 50 mL/min/1.73 m2 HbA1c: 7-10%. Exclusion Criteria: patients with type 1 diabetes; HbA1c <7% or HbA1c >10% fasting blood glucose (FPG) >15 mmol/L (270 mg/dL) at the first visit (screening) and pre-randomization screening women of childbearing potential (if not using proper contraception) history of gastric surgery (including gastric banding within 3 years) history of diabetic ketoacidosis or non-ketogenic hyperosmotic coma average of 3 blood pressure measurements is systolic blood pressure (SBP) >180 mmHg or diastolic blood pressure (DBP) >100 mmHg heart failure NYHA class III or IV AST or ALT greater than 3 times the upper limit of normal systemic corticosteroids have been used for 10 consecutive days within 90 days (topical, eye drop, topical or inhalation agents)
Sites / Locations
- Seoul National University Bundang HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Active Comparator
Dapagliflozin
Lobeglitazone
Dapagliflozin and Lobeglitazone combined
Dapagliflozin 10 mg once daily will be given to participants.
Lobeglitazone 0.5 mg once daily will be given to participants.
Dapagliflozin 10 mg and lobeglitazone 0.5 mg once daily together will be given to participants.